Pimivalimab

Generic Name: Pimivalimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2293951-22-9

Unique Ingredient Identifier: MA05AF40UO

Background: Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: JTX-8064
Drug: pimivalimab

First Posted Date: 2020-12-17

Last Posted Date: 2024-04-09

Lead Sponsor: Jounce Therapeutics, Inc.

Target Recruit Count: 190

Registration Number: NCT04669899

Locations: 🇺🇸
Cedars Sinai, Los Angeles, California, United States
🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States

and more 42 locations

Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

Phase 2

Terminated

Conditions: NSCLC

Interventions: Drug: Pimivalimab
Drug: Vopratelimab

First Posted Date: 2020-09-16

Last Posted Date: 2024-05-22

Lead Sponsor: Jounce Therapeutics, Inc.

Target Recruit Count: 69

Registration Number: NCT04549025

Locations: 🇺🇦
Kyiv Railway Clinical Hospital #3 of Branch Health Center of the PJSC Ukrainian Railway, Kyiv, Ukraine
🇬🇪
Arensia Tbilisi - PPDS, Tbilisi, Georgia
🇭🇺
Veszprem Megyei Tudogyogyintezet, Farkasgyepű, Hungary

and more 69 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy